Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study von GOY, Andre, SINHA, Rajni, WILLIAMS, Michael E, BESISIK, Sevgi Kalayoglu, DRACH, Johannes, RAMCHANDREN, Radhakrishnan, LEI ZHANG, CICERO, Sherri, FU, Tommy, WITZIG, Thomas E

Volltext

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) p... von Goy, Andre, Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Robertson, Michael J., Avivi, Irit, Rowe, Jacob M., Herbrecht, Raoul, Van Hoof, Achiel, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas

Volltext

P3‐018: An Evaluation of the Safety of Nelotanserin, A Highly Potent and Selective 5‐HT2A Inverse Agonist That is Being Developed as a Treatment for Visual Hallucinations and REM B... von Wen, Warren, Ramaswamy, Shankar, Piscitelli, Stephen C., Cicero, Sherri, Lynch, Shau Yu, Friedhoff, Lawrence

Volltext

AN EVALUATION OF THE SAFETY OF NELOTANSERIN, A HIGHLY POTENT AND SELECTIVE 5-HT2A INVERSE AGONIST THAT IS BEING DEVELOPED AS A TREATMENT FOR VISUAL HALLUCINATIONS AND REM BEHAVIOR... von Wen, Warren, Ramaswamy, Shankar, Piscitelli, Stephen C, Cicero, Sherri, Lynch, Shau Yu, Friedhoff, Lawrence

Volltext

Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study von Williams, Michael E., Goy, Andre, Sinha, Rajni, Kalayoglu Besisik, Sevgi, Drach, Johannes W., Ramchandren, Rod, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas E

Volltext

Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib von Goy, Andre, Williams, Michael E., Besisik, Sevgi Kalayoglu, Drach, Johannes, Ramchandren, Radhakrishnan, Robertson, Michael J., Avivi, Irit, Rowe, Jacob M, Herbrecht, Raoul, Van Hoof, Achiel, Egyed, Miklos, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Heise, Carla, Witzig, Thomas E

Volltext

Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma von Witzig, Thomas E., Vose, Julie, Zinzani, Pier Luigi, Habermann, Thomas Matthew, Tuscano, Joseph M., Sinha, Rajni, Williams, Michael E., Drach, Johannes W., Ramchandren, Rod, Kalayoglu Besisik, Sevgi, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Goy, Andre

Volltext

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE... von Goy, Andre, Sinha, Rajni, Williams, Michael E., Besisik, Sevgi Kalayoglu, Drach, Johannes, Ramchandren, Radhakrishnan, Robertson, Michael J., Avivi, Irit, Rowe, Jacob M., Herbrecht, Raoul, Van Hoof, Achiel, Egyed, Miklos, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas E.

Volltext

Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 “EMERGE”... von Goy, Andre, Williams, Michael E, Besisik, Sevgi Kalayoglu, Drach, Johannes, Ramchandren, Radhakrishnan, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas

Volltext